ÂÜÀòÂÒÂ×

Jennifer Petrillo Billet has over 17 years of work experience in the pharmaceutical and healthcare industry. Jennifer currently holds the position of Program Lead, Sage-718 at Sage Therapeutics, where they have been working since August 2022. Prior to this, Jennifer worked as a Senior Director at Sage Therapeutics from September 2021 to August 2022, and as a Director from July 2018 to August 2022.

Before joining Sage Therapeutics, Jennifer served as an Associate Director at Biogen Idec from September 2014 to July 2018. Jennifer also worked at Novartis, where they held the roles of Director of PROs in Global HE&OR from February 2013 to August 2014, and Associate Director of PROs in Global HE&OR from April 2011 to February 2013.

Jennifer's early career includes a role as a PhD Candidate at the London School of Hygiene and Tropical Medicine from October 2007 to March 2011. Their research during this period focused on the development of condition-specific preference-based measures for cost-effectiveness analyses, with a particular emphasis on COPD exacerbations.

Jennifer's work at the United BioSource Corporation from April 2004 to November 2010 provided their with extensive experience in qualitative and quantitative analysis, including the development and validation of patient-reported outcome measures. As a researcher on the EXACT-PRO Initiative, they managed multiple sponsors and worked closely with the US Food and Drug Administration (FDA) for instrument development purposes.

Overall, Jennifer Petrillo Billet's work experience demonstrates their expertise in program leadership, strategic management, and the development of patient-reported outcome measures in the healthcare industry.

Jennifer Petrillo Billet earned a BSc in Economics from Virginia Tech between 1998 and 2002. Jennifer later pursued a PhD in the Faculty of Public Health and Policy, Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine, U. of London from 2007 to 2011.